Briacell Therapeutics Corp (BCTX)

$5.20 -0.83 (-13.76%)
Market Cap 22.37M
Revenue (ttm) 0.00
Net Income (ttm) -4.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,698,700
Avg Vol 1,442,826
Day's Range N/A - N/A
Shares Out 3.71M
Stochastic %K 24%
Beta 1.34
Analysts Strong Sell
Price Target $32.00

Latest News on BCTX

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Apr 24, 2025, 8:00 PM EDT - 1 day ago

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Apr 24, 2025, 10:11 AM EDT - 1 day ago

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

Apr 24, 2025, 7:30 AM EDT - 1 day ago

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

Apr 23, 2025, 7:30 AM EDT - 2 days ago

BriaCell Announces Four Clinical Data Presentations at ASCO 2025

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Apr 22, 2025, 7:30 AM EDT - 3 days ago

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Apr 16, 2025, 7:30 AM EDT - 9 days ago

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Mar 26, 2025, 8:00 AM EDT - 4 weeks ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

Mar 20, 2025, 8:00 AM EDT - 5 weeks ago

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Feb 5, 2025, 6:15 PM EST - 2 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Announces Closing of Public Offering

Feb 5, 2025, 4:05 PM EST - 2 months ago

BriaCell Therapeutics Announces Closing of Public Offering

BriaCell Therapeutics Announces Pricing of Public Offering

Feb 3, 2025, 7:59 PM EST - 2 months ago

BriaCell Therapeutics Announces Pricing of Public Offering

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

Feb 3, 2025, 4:45 PM EST - 2 months ago

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

Feb 3, 2025, 7:30 AM EST - 2 months ago

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

BriaCell Announces Completion of 15:1 Share Consolidation

Jan 27, 2025, 6:42 PM EST - 3 months ago

BriaCell Announces Completion of 15:1 Share Consolidation

BriaCell Announces Proposed Effective Date of Share Consolidation

Jan 3, 2025, 5:05 PM EST - 4 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

Jan 3, 2025, 5:05 PM EST - 4 months ago

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

Dec 17, 2024, 4:05 PM EST - 4 months ago

BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

Dec 17, 2024, 4:05 PM EST - 4 months ago

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

Dec 13, 2024, 4:05 PM EST - 4 months ago

BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

Dec 13, 2024, 7:50 AM EST - 4 months ago

BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

Dec 11, 2024, 11:54 PM EST - 4 months ago

BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

BriaCell Therapeutics Announces Proposed Public Offering

Dec 11, 2024, 4:05 PM EST - 4 months ago

BriaCell Therapeutics Announces Proposed Public Offering

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

Dec 11, 2024, 7:50 AM EST - 4 months ago

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

Dec 2, 2024, 7:50 AM EST - 5 months ago

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

Nov 26, 2024, 7:50 AM EST - 5 months ago

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

BriaCell Provides Update to its Board of Directors

Nov 25, 2024, 7:50 AM EST - 5 months ago

BriaCell Provides Update to its Board of Directors

BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

Nov 21, 2024, 7:50 AM EST - 5 months ago

BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

Nov 8, 2024, 7:50 AM EST - 6 months ago

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

Nov 4, 2024, 7:50 AM EST - 6 months ago

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns

Oct 22, 2024, 2:54 PM EDT - 6 months ago

BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

Oct 22, 2024, 7:50 AM EDT - 6 months ago

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

Oct 15, 2024, 7:50 AM EDT - 6 months ago

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

BriaCell Therapeutics Announces Closing of $5 Million Offering

Oct 2, 2024, 4:05 PM EDT - 7 months ago

BriaCell Therapeutics Announces Closing of $5 Million Offering

BriaCell Therapeutics Announces $5 Million Offering

Oct 1, 2024, 2:05 PM EDT - 7 months ago

BriaCell Therapeutics Announces $5 Million Offering

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor

Oct 1, 2024, 7:50 AM EDT - 7 months ago

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

Sep 18, 2024, 7:50 AM EDT - 7 months ago

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

Sep 12, 2024, 4:05 PM EDT - 8 months ago

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

BriaCell Therapeutics Announces $8.5 Million Offering

Sep 11, 2024, 12:09 PM EDT - 8 months ago

BriaCell Therapeutics Announces $8.5 Million Offering

Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday

Sep 11, 2024, 11:08 AM EDT - 8 months ago

Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

Sep 11, 2024, 7:50 AM EDT - 8 months ago

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer

Sep 10, 2024, 7:50 AM EDT - 8 months ago

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer

BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 9, 2024, 7:50 AM EDT - 8 months ago

BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Jul 18, 2024, 7:56 AM EDT - 10 months ago

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

BriaCell Presents Clinical Efficacy Data at ASCO 2024

Jun 3, 2024, 8:00 AM EDT - 11 months ago

BriaCell Presents Clinical Efficacy Data at ASCO 2024

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

May 24, 2024, 8:00 AM EDT - 1 year ago

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

May 17, 2024, 4:33 PM EDT - 1 year ago

BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

May 15, 2024, 8:00 AM EDT - 1 year ago

BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

BriaCell Announces Oral and Poster Presentations at ASCO 2024

Apr 24, 2024, 8:00 AM EDT - 1 year ago

BriaCell Announces Oral and Poster Presentations at ASCO 2024

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

Apr 10, 2024, 8:00 AM EDT - 1 year ago

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Mar 7, 2024, 8:00 AM EST - 1 year ago

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies